# Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

> **NCT00390806** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 472 (actual)

## Conditions studied

- Lung Cancer, Non-Small Cell

## Interventions

- **DRUG:** HYCAMTIN, oral capsules
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT00390806
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2012-07
- **Final completion:** 2013-09
- **Target enrollment:** 472 (ACTUAL)
- **Last updated:** 2014-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390806, "Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00390806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*